

Amendment to the Claims

Please amend claims 1-12 and 19, cancel claims 13-18 and add new claims 20-29 as follows:

1. (Currently Amended) A T-cell immune response inhibitor that comprises:
a targeted ~~pathogen~~ nucleic acid vaccine and a targeted antigen that is encoded by said nucleic acid vaccine; vaccine's expression protein antigen; or
a targeted ~~pathogen~~ nucleic acid vaccine and an active polypeptide from a targeted antigen that is encoded by said nucleic acid vaccine; vaccine's expression protein antigen's active polypeptide; or
a targeted pathogen nucleic acid vaccine and an inactivated targeted pathogen, and said targeted pathogen's nucleic acid vaccine.
2. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the targeted ~~pathogen~~ nucleic acid vaccine and said targeted antigen that is encoded by said nucleic acid vaccine. vaccine's expression protein antigen.
3. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 2, wherein the ~~physical~~ proportion of said ~~T-cell immune response inhibitor's~~ targeted nucleic acid vaccine and said targeted antigen that is encoded by said nucleic acid vaccine vaccine's expression protein antigen is 2:1 to 10:1.
4. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 3, wherein the ~~physical~~ proportion of said ~~T-cell immune response inhibitor's~~ targeted ~~pathogen~~ nucleic acid vaccine and said targeted antigen that is encoded by said nucleic acid vaccine vaccine's expression protein antigen is 5:1.
5. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the targeted ~~pathogen~~ nucleic acid vaccine and an active polypeptide from a targeted antigen that

is encoded by said nucleic acid vaccine. ~~vaccine's expression protein antigen's active polypeptide.~~

6. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 5, wherein the ~~physical~~ proportion of said ~~T-cell immune response inhibitor's~~ targeted pathogen nucleic acid vaccine and said active polypeptide from a targeted antigen that is encoded by said nucleic acid vaccine ~~vaccine's expression protein antigen's active peptide~~ is 1:5 to 5:1.

7. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 1, wherein said T-cell immune response inhibitor comprises a single package or a mixture of the inactivated targeted pathogen and the targeted pathogen nucleic acid vaccine.

8. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 7, wherein the ~~physical~~ proportion of the inactivated targeted pathogen and the targeted pathogen nucleic acid vaccine ~~in said T-cell immune response inhibitor~~ is 1:2 to 1:10.

9. (Currently Amended) A ~~Any one of the~~ T-cell immune response ~~inhibitors~~ inhibitor according to ~~Patent Claims claim~~ 1 to 8, wherein said T-cell immune response inhibitor also comprises further comprising an immunological adjuvant.

10. (Currently Amended) A ~~Any one of the~~ T-cell immune response ~~inhibitors~~ inhibitor according to ~~Patent Claims claim~~ 1 to 8, wherein said nucleic acid vaccine is a eukaryote cell expression ~~carrier containing~~ vector comprising a protein gene encoding a targeted antigen. ~~encoded gene.~~

11. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 10, wherein the ~~regulatory protein antigen encoded~~ gene encoding the targeted antigen is linked to a promoter selected from the group consisting of: ~~expression promoter in said eukaryote cell expression carrier~~ is RSV, CMV and SV40 viral promoters.

12. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent~~ Claim 10, wherein said eukaryote cell expression ~~carrier~~ vector is a plasmid, ~~expression carrier,~~ virus, or

~~bacteriophage expression carrier, and the expression carrier is formed of plasmid DNA and viral or bacteriophage DNA or the~~ an expression carrier is vector formed of plasmid DNA and a chromosomal DNA fragment.

13-18. (Canceled)

19. (Currently Amended) A T-cell immune response inhibitor according to ~~Patent Claim 18,~~ 7 wherein said inactivated pathogen ~~may be~~ is mixed directly with the nucleic acid vaccine or said inactivated pathogen is emulsified after emulsifying with mineral oil ~~the inactivated pathogen may be~~ and then mixed with the nucleic acid vaccine.

20. (New) A T-cell immune response inhibitor according to claim 10 wherein said nucleic acid vaccine is a plasmid.

21. (New) A T-cell immune response inhibitor according to claim 1 wherein said targeted antigen is a pathogen antigen.

22. (New) A method of inhibiting a T-cell immune response against a targeted antigen that comprises:

administering to an individual, a targeted nucleic acid vaccine and a targeted antigen that is encoded by said nucleic acid; vaccine; or

a targeted nucleic acid vaccine and an active polypeptide from a targeted antigen that is encoded by said nucleic acid vaccine; or

a targeted pathogen nucleic acid vaccine and an inactivated targeted pathogen.

23. (New) A method of treating a disease or condition associated with an autoimmune reaction comprising inhibiting a T-cell immune response by a method according to claim 22.

24. (New) The method of claim 23 wherein the disease or condition is selected from the group consisting of: systemic lupus erythematosus, rheumatoid arthritis, chronic lymphatic thyroiditis, toxic goiter, polyarteritis nodosa, insulin-dependent diabetes mellitus, myasthenia gravis, chronic active hepatitis, chronic ulcerative colitis, pernicious anemia with chronic

atrophic gastritis, allergic encephalomyelitis, Goodpasture's syndrome, scleroderma, common pemphigus, pemphigoid, adrenocortical insufficiency, primary biliary cirrhosis of the liver, multiple sclerosis, and acute polyneuroradiculitis.

25. (New) The method of claim 23 wherein the disease or condition is an autoimmune rejection response in organ transplants.

26. (New) A method of treating allergic reactions comprising inhibiting a T-cell immune response by a method according to claim 22.

27. (New) The method of claim 26 wherein the allergic reactions is to an allergen selected from the group consisting of: dust mites, fleas, cockroaches, animal fur, pollen, mold, and bacteria.

28. (New) The method of claim 26 wherein the allergic reactions is a virus- and tobacco smoke-induced skin and respiratory tract injuries.

29. (New) The method of claim 26 wherein the allergic reactions is an allergic response or immunity overstimulation-induced allergic immune disorders selected from the group consisting of: contact dermatitis, urticaria, allergic rhinitis, asthma, nephritis, hyperthyroidism, and viral hepatitis immuno-hypersensitivity.